Art

J-GLOBAL ID：201502285784717929   Reference number：15A0321394

Risk Factors for Ganciclovir-Induced Thrombocytopenia and Leukopenia

ガンシクロビルによる血小板減少症,白血球減少症のリスク因子

Author (7)： MATSUMOTO Kazuaki (Dep. of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima Univ.) ,  SHIGEMI Akari (Dep. of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima Univ.) ,  IKAWA Kazuro (Dep. of Clinical Pharmacotherapy, Hiroshima Univ.) ,  KANAZAWA Naoko (Dep. of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima Univ.) ,  FUJISAKI Yuko (Dep. of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima Univ.) ,  MORIKAWA Norifumi (Dep. of Clinical Pharmacotherapy, Hiroshima Univ.) ,  TAKEDA Yasuo (Dep. of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima Univ.)
Material： Biological and Pharmaceutical Bulletin  (Biological & Pharmaceutical Bulletin)
Volume： 38  Issue： 2  Page： 235-238 (J-STAGE)  Publication year： 2015 
JST Material Number： S0989A  ISSN： 0918-6158  CODEN： BPBLEO  Document type： Article
Article type： 短報  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： cancer chemotherapy ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=15A0321394&from=J-GLOBAL&jstjournalNo=S0989A") }}

JST classification (2)： Poisoning in general  (GD06010Q) ,  Clinical application of antiviral drugs  (GW17050Z)

Substance index (1)： Ganciclovir

Reference (17)：

• 1) McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs, 61, 1153-1183 (2001).
• 2) Boeckh M, Zaia JA, Jung D, Skettino S, Chauncey TR, Bowden RA. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol. Blood Marrow Transplant., 4, 13-19 (1998).
• 3) Pescovitz MD, Pruett TL, Gonwa T, Brook B, McGory R, Wicker K, Griffy K, Robinson CA, Jung D. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation, 66, 1104-1107 (1998).
• 4) Moretti S, Zikos P, Van Lint MT, Tedone E, Occhini D, Gualandi F, Lamparelli T, Mordini N, Berisso G, Bregante S, Bruno B, Bacigalupo A. Forscarnet vs. ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant., 22, 175-180 (1998).
• 5) Gane E, Saliba F, Valdecasas GJ, O’Grady J, Pescovitz MD, Lyman S, Robinson CA. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet, 350, 1729-1733 (1997).

Terms in the title (4)： ガンシクロビル ,  血小板減少症 ,  白血球減少症 ,  リスク因子